logo-loader
HealthPharma & Biotech
Tissue Regenix Group PLC

New Tissue Regenix CFO to step into role earlier than anticipated

Gareth Jones was supposed to take up his new role at the end of November, but having already completed the handover at his old company, he starts today (Monday)

ribbon being cut
Jones is joining from Applied Graphene Materials

The new chief financial officer of Tissue Regenix Group PLC (LON:TRX) has joined regenerative medical devices company a month earlier than expected.

Gareth Jones’ appointment was first unveiled back in July and he was originally scheduled to take up his new role at the end of November.

READ: Tissue Regenix appoints new CFO

But he has already completed the handover process in his previous position as the chief number cruncher at Applied Graphene Materials PLC (LON:AGM).

“I am delighted to welcome Gareth to the group,” said chief executive Steve Couldwell.

“He will play a pivotal role in the strategic direction, focus and acceleration of our commercial success.

He added: “Utilising his experience and knowledge of both operational and financial enhancement initiatives, alongside his international and listed company experience, we expect Gareth to help execute on our vision and accelerate sustainable long-term shareholder value.”

Quick facts: Tissue Regenix Group PLC

Price: £0.03

Market: AIM
Market Cap: £39.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

RNS

Unaudited Interim Results

1 week, 5 days ago

Appointment of CFO

3 weeks, 4 days ago

Directorate Change

on 08/01/2019

Holding(s) in Company

on 07/08/2019

Result of AGM

on 06/27/2019

Notice of AGM

on 06/04/2019

2 min read